Skip to main content
. 2021 Apr 7;19:1998–2017. doi: 10.1016/j.csbj.2021.04.014

Fig. 2.

Fig. 2

Virtual screening of FDA drugs against Spike protein. (A) The surface view of spike protein where domains are represented in different colors. The ligand binding site is shown inside white dotted circle at RBD (receptor binding domain) of the spike protein. (B) Cartoon depiction of the RBD showing the secondary structure elements and binding of capreomycin. (C) Closeup of RBD-capreomycin (average docking score −9.10) interaction showing residues making hydrogen bonds interactions (red dotted lines) with capreomycin. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)